This protocol applies to patients with Behçet's syndrome who experience recurrent mucocutaneous involvement, including one or more of the following lesion types:
Management targets the local lesions as well as the prevention of their recurrence. The approach involves topical therapy directed at active ulcerations, alongside a systemic agent selected based on the dominant lesion type — particularly when erythema nodosum or genital ulcers are the primary concern.
DOI: 10.1136/annrheumdis-2018-213225
Considering the safety and good tolerability of colchicine, the group agreed that it should be tried first in patients who have only mucocutaneous involvement.
Topical measures such as steroids should be used for the treatment of oral and genital ulcers.
Colchicine should be tried first for the prevention of recurrent mucocutaneous lesions especially when the dominant lesion is erythema nodosum or genital ulcer.
View source ↗